data_DGJ
#
_chem_comp.id                                        DGJ
_chem_comp.name                                      (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol
_chem_comp.type                                      NON-POLYMER
_chem_comp.pdbx_type                                 HETAIN
_chem_comp.formula                                   "C6 H13 N O4"
_chem_comp.mon_nstd_parent_comp_id                   ?
_chem_comp.pdbx_synonyms                             1-deoxygalactonojirimycin
_chem_comp.pdbx_formal_charge                        0
_chem_comp.pdbx_initial_date                         2011-07-01
_chem_comp.pdbx_modified_date                        2011-12-02
_chem_comp.pdbx_ambiguous_flag                       N
_chem_comp.pdbx_release_status                       REL
_chem_comp.pdbx_replaced_by                          ?
_chem_comp.pdbx_replaces                             ?
_chem_comp.formula_weight                            163.172
_chem_comp.one_letter_code                           ?
_chem_comp.three_letter_code                         DGJ
_chem_comp.pdbx_model_coordinates_details            ?
_chem_comp.pdbx_model_coordinates_missing_flag       N
_chem_comp.pdbx_ideal_coordinates_details            Corina
_chem_comp.pdbx_ideal_coordinates_missing_flag       N
_chem_comp.pdbx_model_coordinates_db_code            3S5Y
_chem_comp.pdbx_subcomponent_list                    ?
_chem_comp.pdbx_processing_site                      RCSB

#
loop_
_chem_comp_atom.comp_id                        
_chem_comp_atom.atom_id                        
_chem_comp_atom.alt_atom_id                    
_chem_comp_atom.type_symbol                    
_chem_comp_atom.charge                         
_chem_comp_atom.pdbx_align                     
_chem_comp_atom.pdbx_aromatic_flag             
_chem_comp_atom.pdbx_leaving_atom_flag         
_chem_comp_atom.pdbx_stereo_config             
_chem_comp_atom.model_Cartn_x                  
_chem_comp_atom.model_Cartn_y                  
_chem_comp_atom.model_Cartn_z                  
_chem_comp_atom.pdbx_model_Cartn_x_ideal       
_chem_comp_atom.pdbx_model_Cartn_y_ideal       
_chem_comp_atom.pdbx_model_Cartn_z_ideal       
_chem_comp_atom.pdbx_component_atom_id         
_chem_comp_atom.pdbx_component_comp_id         
_chem_comp_atom.pdbx_ordinal                   
DGJ  C1  C1 C 0 1 N N N 34.520 57.736 32.670 -0.465 -1.736  0.102  C1 DGJ  1
DGJ  C2  C2 C 0 1 N N S 33.115 57.507 32.116 -1.550 -0.673  0.291  C2 DGJ  2
DGJ  O2  O2 O 0 1 N N N 32.394 56.585 32.936 -2.821 -1.219 -0.068  O2 DGJ  3
DGJ  C3  C3 C 0 1 N N R 33.197 57.009 30.672 -1.240  0.531 -0.602  C3 DGJ  4
DGJ  O3  O3 O 0 1 N N N 31.881 56.671 30.190 -2.219  1.549 -0.389  O3 DGJ  5
DGJ  C4  C4 C 0 1 N N S 33.837 58.088 29.798  0.149  1.072 -0.252  C4 DGJ  6
DGJ  O4  O4 O 0 1 N N N 32.966 59.239 29.703  0.157  1.523  1.104  O4 DGJ  7
DGJ  C5  C5 C 0 1 N N R 35.208 58.468 30.354  1.184 -0.041 -0.426  C5 DGJ  8
DGJ  N5  N5 N 0 1 N N N 35.179 58.684 31.797  0.843 -1.169  0.451  N5 DGJ  9
DGJ  C6  C6 C 0 1 N N N 35.735 59.716 29.677  2.571  0.489 -0.057  C6 DGJ 10
DGJ  O6  O6 O 0 1 N N N 37.094 59.911 30.078  3.553 -0.513 -0.330  O6 DGJ 11
DGJ  H1  H1 H 0 1 N N N 35.078 56.789 32.692 -0.676 -2.589  0.748  H1 DGJ 12
DGJ H1A H1A H 0 1 N N N 34.464 58.137 33.693 -0.454 -2.062 -0.938 H1A DGJ 13
DGJ  H2  H2 H 0 1 N N N 32.569 58.462 32.125 -1.571 -0.357  1.334  H2 DGJ 14
DGJ HO2 HO2 H 0 1 N N N 31.524 56.455 32.577 -3.081 -1.988  0.457 HO2 DGJ 15
DGJ  H3  H3 H 0 1 N N N 33.820 56.103 30.629 -1.257  0.222 -1.648  H3 DGJ 16
DGJ HO3 HO3 H 0 1 N N N 31.941 56.363 29.293 -3.124  1.273 -0.587 HO3 DGJ 17
DGJ  H4  H4 H 0 1 N N N 33.981 57.692 28.782  0.394  1.903 -0.914  H4 DGJ 18
DGJ HO4 HO4 H 0 1 N N N 33.374 59.902 29.158 -0.479  2.229  1.287 HO4 DGJ 19
DGJ  H5  H5 H 0 1 N N N 35.876 57.619 30.145  1.188 -0.376 -1.463  H5 DGJ 20
DGJ HN5 HN5 H 0 1 N N N 34.709 59.556 31.935  0.872 -0.895  1.421 HN5 DGJ 21
DGJ  H6  H6 H 0 1 N N N 35.682 59.598 28.585  2.788  1.380 -0.647  H6 DGJ 22
DGJ H6A H6A H 0 1 N N N 35.130 60.585 29.975  2.594  0.741  1.003 H6A DGJ 23
DGJ HO6 HO6 H 0 1 N N N 37.439 60.692 29.661  4.458 -0.244 -0.120 HO6 DGJ 24
#
loop_
_chem_comp_bond.comp_id                  
_chem_comp_bond.atom_id_1                
_chem_comp_bond.atom_id_2                
_chem_comp_bond.value_order              
_chem_comp_bond.pdbx_aromatic_flag       
_chem_comp_bond.pdbx_stereo_config       
_chem_comp_bond.pdbx_ordinal             
DGJ N5  C1 SING N N  1
DGJ C2  C1 SING N N  2
DGJ C1  H1 SING N N  3
DGJ C1 H1A SING N N  4
DGJ C3  C2 SING N N  5
DGJ C2  O2 SING N N  6
DGJ C2  H2 SING N N  7
DGJ O2 HO2 SING N N  8
DGJ C4  C3 SING N N  9
DGJ O3  C3 SING N N 10
DGJ C3  H3 SING N N 11
DGJ O3 HO3 SING N N 12
DGJ O4  C4 SING N N 13
DGJ C4  C5 SING N N 14
DGJ C4  H4 SING N N 15
DGJ O4 HO4 SING N N 16
DGJ C6  C5 SING N N 17
DGJ C5  N5 SING N N 18
DGJ C5  H5 SING N N 19
DGJ N5 HN5 SING N N 20
DGJ C6  O6 SING N N 21
DGJ C6  H6 SING N N 22
DGJ C6 H6A SING N N 23
DGJ O6 HO6 SING N N 24
#
loop_
_pdbx_chem_comp_descriptor.comp_id               
_pdbx_chem_comp_descriptor.type                  
_pdbx_chem_comp_descriptor.program               
_pdbx_chem_comp_descriptor.program_version       
_pdbx_chem_comp_descriptor.descriptor            
DGJ           SMILES              ACDLabs 12.01                                                            OC1C(NCC(O)C1O)CO
DGJ            InChI                InChI  1.03 InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5+,6-/m1/s1
DGJ         InChIKey                InChI  1.03                                                  LXBIFEVIBLOUGU-DPYQTVNSSA-N
DGJ SMILES_CANONICAL               CACTVS 3.370                                           OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
DGJ           SMILES               CACTVS 3.370                                                OC[CH]1NC[CH](O)[CH](O)[CH]1O
DGJ SMILES_CANONICAL "OpenEye OEToolkits" 1.7.2                                       C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O
DGJ           SMILES "OpenEye OEToolkits" 1.7.2                                                        C1C(C(C(C(N1)CO)O)O)O
#
loop_
_pdbx_chem_comp_identifier.comp_id               
_pdbx_chem_comp_identifier.type                  
_pdbx_chem_comp_identifier.program               
_pdbx_chem_comp_identifier.program_version       
_pdbx_chem_comp_identifier.identifier            
DGJ "SYSTEMATIC NAME"              ACDLabs 12.01 (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol
DGJ "SYSTEMATIC NAME" "OpenEye OEToolkits" 1.7.2 (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol
#
loop_
_pdbx_chem_comp_audit.comp_id               
_pdbx_chem_comp_audit.action_type           
_pdbx_chem_comp_audit.date                  
_pdbx_chem_comp_audit.processing_site       
_pdbx_chem_comp_audit.annotator             
_pdbx_chem_comp_audit.details               
DGJ "Create component" 2011-07-01 RCSB EP ?
DGJ  "Modify synonyms" 2011-07-11 RCSB EP ?
#
_pdbe_chem_comp_drugbank_details.comp_id                   DGJ
_pdbe_chem_comp_drugbank_details.drugbank_id               DB05018
_pdbe_chem_comp_drugbank_details.type                      "small molecule"
_pdbe_chem_comp_drugbank_details.name                      Migalastat
_pdbe_chem_comp_drugbank_details.description               "Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A) [FDA Label, F1107, L4274, L4263]. This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other organs [FDA Label, F1107, L4274, L4278]. In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and an estimated more than 50 percent of these diagnosed patients are currently untreated [L4274].  Migalastat (approved and sold under Amicus Therapeutics' brand name Galafold) is subsequently an oral pharmacological chaperone of alpha-Gal A for the treatment of Fabry disease in adults who have amenable GLA variants [FDA Label, F1107, L4274, L4278]. In these patients, migalastat works by stabilizing the body’s own dysfunctional alpha-Gal A enzyme so that it can clear the accumulation of glycosphingolipid disease substrate [FDA Label, F1107, L4274, L4278]. Globally, it is estimated that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants that are treatable with migalastat [L4274].  Given the rarity of Fabry disease and the proportion of Fabry disease patients that could benefit from migalastat therapy, Amicus Therapeutics' brand name Galafold was approved using the Accelerated Approval pathway, under which the FDA may approve drugs for serious conditions where there is an unmet medical need and where a drug is shown to have certain effects that are reasonably likely to predict a clinical benefit to patients [FDA Label, F1107, L4274, L4278]. A further study is required to verify and describe the clinical benefits of Galafold, and the sponsor will be conducting a confirmatory clinical trial of Galafold in adults with Fabry disease [FDA Label, F1107, L4274, L4278].  Additionally, Galafold was alzo granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing where the agency determines that the drug, if approved, would provide a significant improvement in treating, diagnosing or preventing a serious condition over available therapies [FDA Label, F1107]. Galafold also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases [FDA Label, F1107].  As of August 2018, migalastat under Amicus Therapeutics' brand name Galafold is currently approved in Australia, Canada, European Union, Israel, Japan, South Korea, Switzerland, and the United States."
_pdbe_chem_comp_drugbank_details.cas_number                108147-54-2
_pdbe_chem_comp_drugbank_details.mechanism_of_action       "Fabry disease is a progressive X-linked lysosomal storage disorder which affects males and females [FDA Label, F1107]. Fabry disease-causing mutations occur in the galactosidase alpha (GLA) gene and result in a deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A) that is required for glycosphingolipid substrate (GL-3 and lyso-Gb3) metabolism [FDA Label, F1107]. Reduced alpha-Gal A activity is, therefore, associated with the progressive accumulation of glycosphingolipid substrate in vulnerable organs and tissues, which ultimately leads to the morbidity and mortality associated with Fabry disease [FDA Label, F1107].  Certain GLA mutations can result in the production of abnormally folded and unstable mutant forms of alpha-Gal A [FDA Label, F1107]. Migalastat is subsequently a pharmacological chaperone that is designed to selectively and reversibly bind with high affinity to the active sites of certain mutant forms of alpha-Gal A, the genotypes of which are referred to as amenable mutations [FDA Label, F1107]. Such migalastat binding stabilizes these mutant forms of alpha-Gal A in the endoplasmic reticulum and facilitates their proper trafficking to lysosomes [FDA Label, F1107]. Once in the lysosomes and surrounded by an environment defined by lower pH and higher concentrations of relevant glycosphingolipid substrates, migalastat dissociates from alpha-Gal A, thereby restoring the alpha-Gal A activity, leading to the catabolism of glycosphingolipids like globotriaosylceramide (GL-3) and globotriaosylsphingosine (lyso-Gb3) since the alpha-Gal A variants still retain enzymatic activity [FDA Label, F1107].  The GLA mutations that are amenable and not amenable to treatment with migalastat are regularly maintained and updated on online sites that are readily accessible by healthcare providers [FDA Label, F1107]."

#
_pdbe_chem_comp_drugbank_classification.comp_id           DGJ
_pdbe_chem_comp_drugbank_classification.drugbank_id       DB05018
_pdbe_chem_comp_drugbank_classification.parent            Piperidines
_pdbe_chem_comp_drugbank_classification.kingdom           "Organic compounds"
_pdbe_chem_comp_drugbank_classification.class             Piperidines
_pdbe_chem_comp_drugbank_classification.superclass        "Organoheterocyclic compounds"
_pdbe_chem_comp_drugbank_classification.description       "This compound belongs to the class of organic compounds known as piperidines. These are compounds containing a piperidine ring, which is a saturated aliphatic six-member ring with one nitrogen atom and five carbon atoms."

#
_pdbe_chem_comp_drugbank_targets.comp_id                        DGJ
_pdbe_chem_comp_drugbank_targets.drugbank_id                    DB05018
_pdbe_chem_comp_drugbank_targets.name                           "Alpha-galactosidase A"
_pdbe_chem_comp_drugbank_targets.organism                       Humans
_pdbe_chem_comp_drugbank_targets.uniprot_id                     P06280
_pdbe_chem_comp_drugbank_targets.pharmacologically_active       unknown
_pdbe_chem_comp_drugbank_targets.ordinal                        1

#
loop_
_pdbx_chem_comp_synonyms.comp_id          
_pdbx_chem_comp_synonyms.name             
_pdbx_chem_comp_synonyms.provenance       
DGJ                Migalastat   ChEMBL
DGJ     "AT-1001, GR-181314A"   ChEMBL
DGJ 1-Deoxygalactonojirimycin DrugBank
DGJ      1-Deoxygalactostatin DrugBank
DGJ                Migalastat DrugBank
#
loop_
_software.name              
_software.version           
_software.description       
       rdkit 2019.03.2                                      "Core functionality."
pdbeccdutils     0.5.2 "Wrapper to provide 2D templates and molecular fragments."
#
loop_
_pdbe_chem_comp_atom_depiction.comp_id             
_pdbe_chem_comp_atom_depiction.atom_id             
_pdbe_chem_comp_atom_depiction.element             
_pdbe_chem_comp_atom_depiction.model_Cartn_x       
_pdbe_chem_comp_atom_depiction.model_Cartn_y       
_pdbe_chem_comp_atom_depiction.pdbx_ordinal        
DGJ C1 C 5.104 -0.750  1
DGJ C2 C 5.104  0.750  2
DGJ O2 O 3.805  1.500  3
DGJ C3 C 6.404  1.500  4
DGJ O3 O 6.404  3.000  5
DGJ C4 C 7.702  0.750  6
DGJ O4 O 9.002  1.500  7
DGJ C5 C 7.702 -0.750  8
DGJ N5 N 6.404 -1.500  9
DGJ C6 C 9.002 -1.500 10
DGJ O6 O 9.002 -3.000 11
#
loop_
_pdbe_chem_comp_bond_depiction.comp_id            
_pdbe_chem_comp_bond_depiction.atom_id_1          
_pdbe_chem_comp_bond_depiction.atom_id_2          
_pdbe_chem_comp_bond_depiction.value_order        
_pdbe_chem_comp_bond_depiction.bond_dir           
_pdbe_chem_comp_bond_depiction.pdbx_ordinal       
DGJ N5 C1 SINGLE       NONE  1
DGJ C2 C1 SINGLE       NONE  2
DGJ C3 C2 SINGLE       NONE  3
DGJ C2 O2 SINGLE BEGINWEDGE  4
DGJ C4 C3 SINGLE       NONE  5
DGJ O3 C3 SINGLE  BEGINDASH  6
DGJ O4 C4 SINGLE  BEGINDASH  7
DGJ C4 C5 SINGLE       NONE  8
DGJ C6 C5 SINGLE BEGINWEDGE  9
DGJ C5 N5 SINGLE       NONE 10
DGJ C6 O6 SINGLE       NONE 11
#
_pdbe_chem_comp_substructure.comp_id                      DGJ
_pdbe_chem_comp_substructure.substructure_name            MurckoScaffold
_pdbe_chem_comp_substructure.id                           S1
_pdbe_chem_comp_substructure.substructure_type            scaffold
_pdbe_chem_comp_substructure.substructure_smiles          C1CCNCC1
_pdbe_chem_comp_substructure.substructure_inchis          InChI=1S/C5H11N/c1-2-4-6-5-3-1/h6H,1-5H2
_pdbe_chem_comp_substructure.substructure_inchikeys       NQRYJNQNLNOLGT-UHFFFAOYSA-N

#
loop_
_pdbe_chem_comp_substructure_mapping.comp_id                    
_pdbe_chem_comp_substructure_mapping.atom_id                    
_pdbe_chem_comp_substructure_mapping.substructure_id            
_pdbe_chem_comp_substructure_mapping.substructure_ordinal       
DGJ C1 S1 1
DGJ C2 S1 1
DGJ C3 S1 1
DGJ C4 S1 1
DGJ C5 S1 1
DGJ N5 S1 1
#
_pdbe_chem_comp_rdkit_properties.comp_id                               DGJ
_pdbe_chem_comp_rdkit_properties.exactmw                               163.084
_pdbe_chem_comp_rdkit_properties.lipinskiHBA                           5
_pdbe_chem_comp_rdkit_properties.lipinskiHBD                           5
_pdbe_chem_comp_rdkit_properties.NumRotatableBonds                     5
_pdbe_chem_comp_rdkit_properties.NumHBD                                5
_pdbe_chem_comp_rdkit_properties.NumHBA                                5
_pdbe_chem_comp_rdkit_properties.NumHeteroatoms                        5
_pdbe_chem_comp_rdkit_properties.NumAmideBonds                         0
_pdbe_chem_comp_rdkit_properties.FractionCSP3                          1
_pdbe_chem_comp_rdkit_properties.NumRings                              1
_pdbe_chem_comp_rdkit_properties.NumAromaticRings                      0
_pdbe_chem_comp_rdkit_properties.NumAliphaticRings                     1
_pdbe_chem_comp_rdkit_properties.NumSaturatedRings                     1
_pdbe_chem_comp_rdkit_properties.NumHeterocycles                       1
_pdbe_chem_comp_rdkit_properties.NumAromaticHeterocycles               0
_pdbe_chem_comp_rdkit_properties.NumSaturatedHeterocycles              1
_pdbe_chem_comp_rdkit_properties.NumAliphaticHeterocycles              1
_pdbe_chem_comp_rdkit_properties.NumSpiroAtoms                         0
_pdbe_chem_comp_rdkit_properties.NumBridgeheadAtoms                    0
_pdbe_chem_comp_rdkit_properties.NumAtomStereoCenters                  0
_pdbe_chem_comp_rdkit_properties.NumUnspecifiedAtomStereoCenters       0
_pdbe_chem_comp_rdkit_properties.labuteASA                             82.954
_pdbe_chem_comp_rdkit_properties.tpsa                                  92.950
_pdbe_chem_comp_rdkit_properties.CrippenClogP                          -2.967
_pdbe_chem_comp_rdkit_properties.CrippenMR                             36.897
_pdbe_chem_comp_rdkit_properties.NumHeavyAtoms                         11

#
loop_
_pdbe_chem_comp_external_mappings.comp_id           
_pdbe_chem_comp_external_mappings.source            
_pdbe_chem_comp_external_mappings.resource          
_pdbe_chem_comp_external_mappings.resource_id       
DGJ UniChem    ChEMBL     CHEMBL110458
DGJ UniChem  DrugBank          DB05018
DGJ UniChem     ChEBI           135923
DGJ UniChem      ZINC ZINC000001636704
DGJ UniChem BindingDb         50163440
#
loop_
_pdbe_chem_comp_rdkit_conformer.comp_id             
_pdbe_chem_comp_rdkit_conformer.atom_id             
_pdbe_chem_comp_rdkit_conformer.Cartn_x_rdkit       
_pdbe_chem_comp_rdkit_conformer.Cartn_y_rdkit       
_pdbe_chem_comp_rdkit_conformer.Cartn_z_rdkit       
_pdbe_chem_comp_rdkit_conformer.rdkit_method        
_pdbe_chem_comp_rdkit_conformer.rdkit_ordinal       
DGJ  C1 -0.246 -0.047  1.643 ETKDGv2  1
DGJ  C2 -1.470  0.057  0.723 ETKDGv2  2
DGJ  O2 -2.383  0.965  1.283 ETKDGv2  3
DGJ  C3 -1.034  0.540 -0.675 ETKDGv2  4
DGJ  O3 -2.128  0.621 -1.557 ETKDGv2  5
DGJ  C4  0.073 -0.369 -1.254 ETKDGv2  6
DGJ  O4 -0.446 -1.644 -1.546 ETKDGv2  7
DGJ  C5  1.249 -0.530 -0.257 ETKDGv2  8
DGJ  N5  0.785 -0.937  1.086 ETKDGv2  9
DGJ  C6  2.150  0.721 -0.192 ETKDGv2 10
DGJ  O6  3.249  0.489  0.648 ETKDGv2 11
DGJ  H1  0.181  0.960  1.837 ETKDGv2 12
DGJ H1A -0.570 -0.449  2.627 ETKDGv2 13
DGJ  H2 -1.936 -0.954  0.650 ETKDGv2 14
DGJ HO2 -3.269  0.769  0.878 ETKDGv2 15
DGJ  H3 -0.624  1.568 -0.575 ETKDGv2 16
DGJ HO3 -2.604 -0.250 -1.540 ETKDGv2 17
DGJ  H4  0.465  0.098 -2.189 ETKDGv2 18
DGJ HO4 -0.798 -1.613 -2.474 ETKDGv2 19
DGJ  H5  1.896 -1.346 -0.651 ETKDGv2 20
DGJ HN5  0.390 -1.905  1.026 ETKDGv2 21
DGJ  H6  2.537  0.940 -1.209 ETKDGv2 22
DGJ H6A  1.591  1.622  0.141 ETKDGv2 23
DGJ HO6  2.940  0.657  1.576 ETKDGv2 24
#
